首页> Journal of comparative effectiveness research> A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

导出 OA

翻译打印收藏纠错

第一作者： Kerry A,Rogers

第一单位： Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.

作者： Kerry A,Rogers ^[1] ; Benyam,Muluneh ^[2] ; Zaina P,Qureshi ^[3] ; Jinghua,He ^[3] ; Alex,Bokun ^[3] ; Zhijie,Ding ^[3] ; Marie-Hélène,Lafeuille ^[4] ; Priyanka,Gogna ^[4] ; Bruno,Emond ^[4] ; Michael,Fradley ^[5]

作者单位： Division of Hematology, The Ohio State University, Columbus, OH 43210, USA. ^[1] Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. ^[2] Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA 19044, USA. ^[3] Analysis Group, Inc., Montréal, QC H3B 0G7, Canada. ^[4] Thalheimer Center for Cardio-Oncology, Abramson Cancer Center & Division of Cardiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA. ^[5]

关键词 EMR acalabrutinib chronic lymphocytic leukemia claims data cost comparison costs healthcare resource use ibrutinib real-world study small lymphocytic lymphoma